Cargando…

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab

Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction and death. The purpose of the present study is to determine clinical characteristics associated with 28 day in-hospital survival in patients with coronavirus disease 2019 (COVID-19) that rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morrison, Austin R., Johnson, Joseph M., Griebe, Kristin M., Jones, Mathew C., Stine, John J., Hencken, Laura N., To, Long, Bianchini, Monica L., Vahia, Amit T., Swiderek, Jennifer, Ramesh, Mayur S., Peters, Michael A., Smith, Zachary R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332925/ https://www.ncbi.nlm.nih.gov/pubmed/32646770 http://dx.doi.org/10.1016/j.jaut.2020.102512

Ejemplares similares

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19
por: Fadel, Raef, et al.
Publicado: (2020)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit
por: Suleyman, Geehan, et al.
Publicado: (2020)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019
por: Lewis, Tyler C., et al.
Publicado: (2020)

Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
por: Sirimaturos, Michael, et al.
Publicado: (2020)

Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)
por: Chen, Chong-xiang, et al.
Publicado: (2021)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
por: Sinha, Pranay, et al.
Publicado: (2021)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

444. Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers in Southeast Michigan
por: Vahia, Amit T, et al.
Publicado: (2020)

Coronavirus Disease 2019 Vaccine Barriers: Educating Patients to Alleviate Fear of Receiving the Vaccine
por: Alexander, Kristin
Publicado: (2021)

Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
por: Abdullah, Shazia, et al.
Publicado: (2021)

Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study
por: Kuwahara, Masaatsu, et al.
Publicado: (2022)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Effect of tocilizumab treatment in mildly-obese patients with coronavirus disease 2019: a case series
por: Abe, Takashi, et al.
Publicado: (2022)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
por: Tom, Jennifer, et al.
Publicado: (2021)

Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series
por: Cui, Ran, et al.
Publicado: (2021)

551. Convalescent plasma early in disease course improves survival in COVID-19
por: Nauriyal, Varidhi, et al.
Publicado: (2020)

56. Could Maturation Effect Contribute to In-hospital Mortality Improvement During COVID-19 Pandemic?
por: Maki, Gina, et al.
Publicado: (2020)

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
por: Veiga, Viviane C, et al.
Publicado: (2021)

Low- Versus High-Dose Methylprednisolone in Adult Patients With Coronavirus Disease 2019: Less Is More
por: Joshi, Seema, et al.
Publicado: (2021)

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
por: Zhang, Shengyu, et al.
Publicado: (2020)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

Evaluation of Hypertriglyceridemia in Critically Ill Patients With Coronavirus Disease 2019 Receiving Propofol
por: Kovacevic, Mary P., et al.
Publicado: (2021)

Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
por: Mori, Shunsuke, et al.
Publicado: (2013)

Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy
por: Lebedeva, Anna, et al.
Publicado: (2022)

Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)
por: Lohse, Anne, et al.
Publicado: (2020)

522. The Simple and Novel SAS Score to Predict Mortality at Presentation in 2541 Hospitalized COVID-19 Patients
por: Acosta, Tommy J Parraga, et al.
Publicado: (2020)

Necrotizing fasciitis with slow progression in a patient with rheumatoid arthritis receiving tocilizumab
por: Goto, Kazuya, et al.
Publicado: (2022)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kqgdil2vmjhv055kvn77b779u3